ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Cohort Study |
Article Title |
Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Hyoung Su Kim, Hyung Joon Yim, Myoung Kuk Jang, Ji Won Park, Sang Jun Suh, Yeon Seok Seo, Ji Hoon Kim, Bo Hyun Kim, Sang Jong Park, Sae Hwan Lee, Sang Gyune Kim, Young Seok Kim, Jung Il Lee, Jin-Woo Lee, In Hee Kim, Tae Yeob Kim, Jin-Wook Kim, Sook-Hyang Jeong, Young Kul Jung, Hana Park and Seong Gyu Hwang; on behalf of Antiviral Resistance Study Group |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Korean Association for the Study of the Liver (in part) |
|
|
Corresponding Author |
Hyung Joon Yim, MD, PhD, Department of Internal Medicine, Korea University Ansan Hospital, 123 Jeokgeum-ro, Danwon-Gu, Ansan-Si, Gyeonggi-Do 425-707, South Korea. gudwns21@medimail.co.kr |
Key Words |
Adefovir; Chronic hepatitis B; Entecavir; Lamivudine; Resistance |
Core Tip |
Studies regarding optimal treatment strategies for entecavir-resistant chronic hepatitis B are sparse. Tenofovir may be the best option, but it is still not available in many countries. Where tenofovir is not available, adefovir plus entecavir can be considered an alternative treatment option in patients with favorable predictive factors. These factors included lower baseline hepatitis B virus (HBV) DNA levels (< 5.2 log10 IU/mL) and reduction of HBV DNA < 3.3 log10 IU/mL after 3 mo of treatment in our study. The present study will guide the treatment of entecavir-resistant chronic hepatitis B. |
Publish Date |
2015-10-14 12:06 |
Citation |
Kim HS, Yim HJ, Jang MK, Park JW, Suh SJ, Seo YS, Kim JH, Kim BH, Park SJ, Lee SH, Kim SG, Kim YS, Lee JI, Lee JW, Kim IH, Kim TY, Kim JW, Jeong SH, Jung YK, Park H, Hwang SG; on behalf of Antiviral Resistance Study Group. Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies. World J Gastroenterol 2015; 21(38): 10874-10882 |
URL |
http://www.wjgnet.com/1007-9327/full/v21/i38/10874.htm |
DOI |
http://dx.doi.org/10.3748/wjg.v21.i38.10874 |